Wolwo Bio (300357.SZ) received approval for clinical trials of human umbilical cord mesenchymal stem cell type II injection

Zhitong Finance APP News, Wolwo Bio (300357.SZ) announced that recently, the company's indirect controlling subsidiary Zhejiang Wolwo Stem Cell Technology Co., Ltd. (hereinafter referred to as "Zhejiang Stem Cell") downloaded and obtained the "Drug Clinical Trial Approval Notice" from the government service portal website of the National Medical Products Administration. The drug clinical trial application for "Human Umbilical Cord Mesenchymal Stem Cell Type II Injection" (hereinafter referred to as "this product") submitted by Zhejiang Stem Cell has been approved.